



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/837,604	04/18/2001	Oleg V. Bougri	38-21(51892)B

CONFIRMATION NO. 3406

Lawrence M. Lavin, Jr.  
Patent Department, E2NA  
Monsanto Company  
800 N. Lindbergh Boulevard  
St. Louis, MO 63167

**FORMALITIES LETTER**

\*OC000000008999055\*

Date Mailed: 10/24/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

*M. Marshall*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re applications of:

Oleg V. Bougri *et al.*

Appln. No.: 09/837,604

Filed: April 18, 2001

For: Nucleic Acid Molecules and Other Molecules  
Associated With Plants

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 38-21(51892)B

**Response to Notice to Comply With Requirements For Patent Applications Containing  
Nucleotide Sequence And/Or Amino Acid Sequence Disclosures**

Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Notice to Comply of Nonprovisional Application - Filing Date Granted dated April 18, 2001, Applicants submit the following documents for appropriate action by the U.S. Patent and Trademark Office:


1. Copy of Notice to Comply of Nonprovisional Application- mailed on October 24, 2002;
2. Response to Notice to Comply – in duplicate;
3. Certificate of mailing for Response to Notice to Comply of Nonprovisional Application;
4. Copy of Sequence Listing in (CRF);
5. Statement Regarding Sequence Submission; and
6. (1) return-receipt prepaid postcard.

It is respectfully requested that the attached prepaid postcard be stamped with the date of filing of these documents, and that it be returned as soon as possible.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 13-4125. If extensions of time under 37 C.F.R. § 1.136 other than those otherwise provided for herewith are required to prevent abandonment of the present patent application, then such extensions of time are hereby

petitioned, and any fees therefore are hereby authorized to be charged to our Deposit Account No. 13-4125. A duplicate copy of this Response is enclosed.


Respectfully submitted,



Lawrence M. Lavin, Jr.  
(Reg. No.: 30768)

Date: 12/5/02

Patent Department, E2NA Monsanto Company  
800 North Lindbergh Blvd.  
St. Louis, MO 63167  
Tel: 314-694-3602  
Fax: 314-694-1671



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re applications of:

Oleg V. Bougri et al.

Appln. No.: 09/837,604

Filed: April 18, 2001

For: Nucleic Acid Molecules and Other Molecules  
Associated with Plants

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 38-21(51892)B

Commissioner for Patents  
Washington, DC 20231

**Certificate of Mailing**

I hereby certify that this Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington DC, 20231

on

12/5/02

GRACIE WILLIAMS  
(Printed name of person signing this certificate)

Gracie Williams  
(Signature)



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
Washington, DC 20231

Re: U.S. Utility Patent Application No. 09/837,604  
Filed: April 18, 2001  
For: **Nucleic Acid Molecules And Other Molecules Associated With Plants**  
Inventors: Oleg V. BOUGRI *et al.*  
Atty. Docket: 38-21(51892)B

Sir:


Transmitted herewith for appropriate action by the U.S. Patent and Trademark Office (USPTO) are the following documents:

1. (CRF) Copy of Sequence Listing ;
2. Statement Regarding Sequence Submission;
3. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
4. Response to Notice to Comply;
5. Certificate of mailing for Response to Notice to Comply;
6. (1) Return receipt-postcard.

It is respectfully requested that the attached postcard be stamped with the date of Filing of these documents, and that it be returned to us. In the event that extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 13-4125, referencing matter number 38-21(51892)B.

Respectfully submitted,



Lawrence M. Lavin, Jr. (Reg. No. 30,768)

Date: 12/8/02

Patent Department, E2NA Monsanto Company  
800 N. Lindbergh Blvd.  
St. Louis, Mo. 63167  
Tel: 314-694-3602  
FAX: 314-694-1671